Male sex hormones are often viewed in isolation, but testosterone, DHT, and estradiol actually function as an interconnected system supporting long-term health.
Male sex hormones are not isolated chemicals operating in opposition to one another. They form an integrated, responsive steroid network. In popular culture, testosterone is often labeled the primary male hormone, dihydrotestosterone (DHT) is blamed for hair loss or prostate issues, and estradiol is dismissed as a female hormone that men should avoid.
This guide examines what male sex hormones actually are and how they function. It reviews the biological pathways that connect testosterone, DHT, and estradiol, moving past simplistic good versus bad labels. You will learn where these hormones originate, how tissues process them locally, and what current clinical evidence says about their roles across a man's life.
This article is for educational and informational purposes only and does not constitute personal medical advice. Hormonal evaluation and treatment decisions require comprehensive assessment by a qualified healthcare professional. Always consult a physician regarding lab results, symptoms, or medical conditions.
The relationship among male sex hormones is defined by metabolic conversion rather than independent competition. The following points summarize the established clinical and biological consensus:
Male sexual differentiation, development, and ongoing physiological maintenance rely on steroidogenesis. Steroidogenesis is the biological process that converts cholesterol into active steroid hormones. Within this network, testosterone occupies a central hub position. It acts directly on androgen receptors in certain tissues, but it also serves as the direct raw material for both DHT and estradiol.
A practical framework for understanding this system is the four-step sequence: precursor, local conversion, receptor, and tissue outcome. Cholesterol is transformed through intermediate steroids into testosterone. Once testosterone enters the bloodstream or target tissues, local enzymes determine its ultimate metabolic fate. If the enzyme 5-alpha-reductase is present, testosterone becomes DHT. If the enzyme aromatase is present, testosterone becomes estradiol.
This metabolic structure means that testosterone, DHT, and estradiol cannot be viewed as separate, competing agents. Increasing or decreasing testosterone availability naturally affects the supply of precursor available for conversion into DHT and estradiol. Conversely, blocking the enzymes responsible for conversion alters the balance of downstream hormones and leaves more unconverted testosterone in circulation.
Tissue-specific action explains why circulating blood concentrations do not always reveal how much active hormone a specific organ experiences. For instance, the prostate contains high concentrations of 5-alpha-reductase. As a result, prostate tissue experiences a potent androgenic environment dominated by DHT even when circulating blood levels of DHT appear relatively modest. To understand male endocrinology, one must look at both systemic circulation and localized cellular activity. Readers interested in foundational testosterone biology can see how these pathways establish base hormone production across the lifespan.
Testosterone is the primary circulating androgen in adult men. It is responsible for classical male secondary sexual characteristics, nitrogen retention in muscle tissue, stimulation of erythropoiesis, and maintenance of bone strength. Beyond these direct actions, it sustains male reproductive capacity by supporting spermatogenesis within the testes.
The vast majority of testosterone production occurs in the testes. Specialized cells called Leydig cells reside in the interstitial tissue between the seminiferous tubules. Under the control of the hypothalamic-pituitary-gonadal axis, the pituitary gland secretes luteinizing hormone (LH) into circulation. Leydig cells respond directly to LH stimulation, producing an estimated 5 to 10 mg of testosterone daily in healthy adult men.
More than 95 percent of all circulating testosterone in men is produced by the testes under LH regulation. The adrenal glands synthesize the small remaining fraction, primarily as weaker precursor androgens such as dehydroepiandrosterone (DHEA) and androstenedione. These adrenal androgens can undergo peripheral conversion into testosterone, but their contribution is minor compared to testicular output.
Once secreted into the bloodstream, testosterone is largely bound to plasma transport proteins. Because steroid hormones are lipophilic, they do not dissolve freely in water-based blood plasma. The body utilizes two main carrier proteins to transport testosterone through circulation:
The fraction of testosterone bound tightly to SHBG is generally unavailable for immediate entry into target cells. In contrast, the fraction bound loosely to albumin easily dissociates in capillary beds. This albumin-bound fraction, combined with the completely unattached free testosterone, is collectively referred to as bioavailable testosterone.
Clinical reference materials vary somewhat in their published binding ranges. One standard clinical reference indicates that approximately 40 percent of circulating testosterone is bound to SHBG, 58 percent is bound to albumin, and roughly 2 percent remains free. Other literature reports that SHBG-bound testosterone can range from 50 to 80 percent, with albumin-bound hormone making up 20 to 50 percent, and free hormone accounting for 2 to 3 percent. These variations highlight that protein binding is a dynamic biological state rather than a rigid, identical percentage for every individual. When evaluating blood tests, clinicians look at both total levels and protein binding patterns, as detailed in our guide on testing and biomarker evaluation.
Dihydrotestosterone is often described narrowly in commercial health discussions as a harmful hormone responsible for male pattern baldness and benign prostatic hyperplasia. In male physiology, however, DHT is an essential, highly potent androgen. It carries distinct structural and biological properties that make it uniquely suited for specific developmental and tissue-level tasks.
DHT is formed when the enzyme 5-alpha-reductase transfers two hydrogen atoms to the carbon-4 and carbon-5 double bond of the testosterone molecule. This enzymatic reduction increases the steroid's affinity for the androgen receptor. DHT binds to the human androgen receptor with an affinity several times higher than testosterone. It also dissociates from the receptor at a significantly slower rate, resulting in a more sustained and potent intracellular androgenic signal.
The human body expresses multiple isozymes of 5-alpha-reductase, notably type 1 and type 2:
Unlike testosterone, DHT cannot be converted into estradiol by the aromatase enzyme. This makes DHT a purely androgenic steroid. It can, however, be metabolized downstream into other intermediates, such as 3-beta-androstanediol, which interacts with estrogen receptor pathways.
The clearest demonstration of DHT's unique role comes from individuals born with congenital 5-alpha-reductase type 2 deficiency. This rare genetic condition impairs the body's ability to convert testosterone to DHT during fetal development. Because testosterone production remains intact, these individuals provide a natural model showing which male characteristics require DHT and which require only testosterone.
During embryogenesis, testosterone directly mediates the differentiation of the internal Wolffian duct structures into the epididymides, vas deferens, and seminal vesicles. In contrast, DHT is strictly required for the virilization of the external male genitalia, including the penis and scrotum, as well as the prostate gland. Infants with 5-alpha-reductase deficiency are often born with undervirilized or ambiguous external genitalia and a rudimentary or absent prostate.
At puberty, when testicular testosterone production surges dramatically, individuals with this condition experience normal voice deepening, increased muscle mass, and normal linear growth. However, they typically exhibit minimal prostate enlargement, reduced facial and body hair, and an absence of androgenetic alopecia. This clinical reality proves that testosterone and DHT are not interchangeable and that each drives separate anatomical and physiological outcomes.
In adult men, DHT remains the primary intracellular androgen within the prostate gland and hair follicles. Because 5-alpha-reductase is expressed locally in these tissues, circulating serum measurements of DHT do not accurately capture the androgenic tone inside the tissue itself.
Medical therapies that inhibit 5-alpha-reductase, such as finasteride and dutasteride, work by lowering intracellular DHT concentrations in the prostate and scalp. In the prostate, lowering local DHT decreases cellular proliferation, making these medications useful for managing benign prostatic hyperplasia. On the scalp, reducing DHT exposure slows the miniaturization of genetically susceptible hair follicles. These targeted pharmaceutical effects reflect tissue-specific pharmacology rather than a systemic mandate to eradicate DHT from the entire body.
Estradiol is commonly misunderstood as a female hormone that causes negative side effects when present in the male body. In reality, estradiol is an essential regulator of male metabolic, skeletal, and sexual health. Complete absence or excessive suppression of estradiol leads to severe physiological dysfunction.
Men do not produce large quantities of estradiol directly in the gonads. Instead, circulating estradiol is generated primarily through the conversion of circulating androgens by the aromatase enzyme (CYP19A1). Aromatase converts testosterone into estradiol and androstenedione into estrone.
Clinical endocrinology references estimate that a healthy adult male produces roughly 50 micrograms of estradiol each day. Of this total daily amount:
Adipose tissue represents the largest peripheral site of aromatase activity. Other significant sites of aromatization include skeletal muscle, the brain, bone tissue, vascular endothelium, and skin. Because fat cells express aromatase, overall body fat percentage strongly influences the rate of peripheral conversion from testosterone to estradiol.
The biological necessity of estradiol in men is most clearly illustrated in bone physiology. During pubertal growth, testosterone stimulates periosteal bone expansion, increasing bone diameter. However, estradiol is the primary hormone responsible for epiphyseal plate closure, which terminates longitudinal bone growth in young men.
In adult life, both testosterone and estradiol are required to maintain skeletal strength, but estradiol plays the dominant role in suppressing bone resorption. Men born with congenital aromatase deficiency or complete estrogen receptor resistance continue growing tall into adulthood because their growth plates fail to fuse. These individuals also suffer from severe early-onset osteopenia and low bone mineral density despite having normal or elevated circulating testosterone levels.
When adult men with aromatase deficiency receive controlled estradiol replacement, their growth plates fuse and their bone mineral density improves dramatically. Clinical reviews indicate that an estradiol threshold of approximately 15 to 25 pg/mL (55 to 92 pmol/L) is generally required to preserve adult male skeletal integrity. Sustained estradiol levels below 10 pg/mL are associated with significantly increased bone resorption markers and progressive bone loss.
Estradiol plays a direct role in regulating male sexual behavior, central nervous system signaling, and body fat distribution. Within the brain, local aromatization of testosterone to estradiol is involved in the central regulation of sexual desire and mood. Estradiol also participates in the negative feedback loop at the hypothalamus and pituitary gland, modulating the secretion of LH and follicle-stimulating hormone (FSH).
Research examining selective hormone suppression in men demonstrates that estradiol deficiency increases both subcutaneous and intra-abdominal visceral fat. While testosterone largely governs fat-free mass and muscle size, estradiol acts as an essential regulator of adipose tissue metabolism. Suppressing estradiol alongside testosterone leads to faster accumulation of body fat than suppressing testosterone alone.
The precise functions of testosterone, DHT, and estradiol have been clarified by clinical studies that systematically block individual enzymes or receptors. Rather than guessing the role of a hormone, researchers observe what happens when that specific hormone is selectively removed while other steroids remain stable.
Randomized clinical trials have evaluated healthy men who received medications to suppress endogenous hormone production, followed by add-back regimens of testosterone with or without the aromatase inhibitor anastrozole. These studies demonstrate clear physiological divisions between testosterone-mediated actions and estradiol-mediated actions.
Men who received adequate testosterone replacement but had their estradiol conversion blocked by anastrozole experienced notable changes:
These findings show that testosterone alone cannot maintain male sexual health and body composition if estradiol is severely suppressed. Preserving a balanced physiological level of estradiol is necessary for overall metabolic and sexual function.
Blocking 5-alpha-reductase with drugs like finasteride or dutasteride selectively reduces DHT while maintaining or slightly increasing circulating testosterone and estradiol. Clinical trials monitoring men on long-term 5-alpha-reductase inhibitors show that suppressing DHT produces predictable, localized changes without abolishing systemic androgenic function.
In these men, intraprostatic DHT concentrations drop by 80 to 90 percent, leading to measurable reductions in prostate volume and decreased serum prostate-specific antigen (PSA) levels. On the scalp, lower DHT concentrations arrest follicular miniaturization in most men with androgenetic alopecia.
Importantly, fat-free muscle mass, physical strength, and erythropoiesis remain largely intact during 5-alpha-reductase inhibition. This occurs because skeletal muscle tissue lacks significant 5-alpha-reductase expression and responds directly to circulating testosterone. However, a small subset of men report adverse sexual symptoms, illustrating that individual sensitivity to altered androgen ratios varies across the population.
Interpreting male sex hormones requires a structured approach that avoids relying on isolated laboratory numbers. A single blood test provides only a snapshot of circulating hormone levels. It does not measure receptor sensitivity, cellular enzyme activity, or daily biological variations.
Major clinical guidelines, including those from the Endocrine Society, the American Urological Association (AUA), and the European Association of Urology (EAU), agree on fundamental diagnostic criteria. A diagnosis of hypogonadism cannot be made from blood work alone. It requires the documented presence of persistent, compatible clinical symptoms combined with reliably low circulating testosterone on repeated testing. Men experiencing potential hormonal shifts can read more about evaluating low testosterone symptoms in our dedicated clinical reviews.
Because testosterone exhibits a natural circadian rhythm, peaking in the early morning and declining through the afternoon, blood samples must be drawn between 8:00 AM and 10:00 AM in a fasted state. Acute illness, poor sleep, extreme psychological stress, and heavy alcohol intake can cause temporary drops in testosterone. Consequently, clinical guidelines recommend confirming any low result with a second morning test drawn on a separate day before establishing a diagnosis.
Different professional organizations specify slightly different total testosterone thresholds for clinical decision-making:
These threshold differences show that guidelines provide structured reference points rather than absolute, rigid biological boundaries.
A thorough hormonal assessment often examines a broader panel of interconnected biomarkers rather than relying on total testosterone in isolation.
When total testosterone falls into a borderline range, measuring free or bioavailable testosterone provides valuable clarity. In men with altered SHBG levels, total testosterone can give a misleading impression of androgen availability. Free testosterone can be measured directly via equilibrium dialysis, which is considered the gold standard, or calculated using validated formulas based on total testosterone, SHBG, and albumin levels.
SHBG concentrations vary significantly based on underlying metabolic and systemic conditions. Factors that elevate SHBG include advancing age, hyperthyroidism, caloric restriction, and elevated circulating estrogens.
Conversely, factors that lower SHBG include obesity, hyperinsulinemia, type 2 diabetes, hypothyroidism, and the use of exogenous androgens. When SHBG is very low, a man may have low total testosterone while maintaining normal free testosterone. When SHBG is unusually high, total testosterone may appear normal while free testosterone is clinically deficient.
Pituitary gonadotropins are essential for distinguishing between primary and secondary testicular failure. Elevated LH and FSH paired with low testosterone indicate primary hypogonadism, meaning the testes themselves have reduced capacity to produce hormones. Low or inappropriately normal LH and FSH paired with low testosterone indicate secondary hypogonadism, pointing to an issue in hypothalamic or pituitary signaling.
Evaluating estradiol in men presents technical challenges. Standard direct immunoassays used widely by commercial laboratories were designed primarily to measure the high estradiol concentrations found in women. These standard assays frequently suffer from cross-reactivity and poor precision in the low concentration range typical of healthy men (10 to 40 pg/mL).
When precise estradiol evaluation is clinically necessary, clinical guidelines favor liquid chromatography-tandem mass spectrometry (LC-MS/MS). Mass spectrometry provides high sensitivity and eliminates interference from other circulating steroids, ensuring reliable measurement of low male estradiol levels.
Routine measurement of serum DHT is rarely indicated in standard clinical evaluations. Because DHT acts primarily as a localized, paracrine, and autocrine hormone, circulating blood levels do not accurately reflect intracellular tissue activity. Serum DHT testing is primarily reserved for specific pediatric diagnostic workups, such as investigating suspected 5-alpha-reductase deficiency in infants with atypical genitalia.
When evaluating information about sex hormones, it is vital to separate established clinical guidance from emerging research, small-scale trials, and unproven claims. The quality of evidence varies considerably across different hormone-related topics.
Robust evidence from large-scale randomized controlled trials and validated clinical practice guidelines supports several core principles:
Regulatory agencies continue to review the safety profile of hormone replacement therapies. For example, the United States Food and Drug Administration (FDA) established class-wide labeling changes for prescription testosterone products regarding cardiovascular risks. These updates followed completed ambulatory blood-pressure monitoring studies demonstrating that exogenous testosterone can cause modest increases in blood pressure.
Healthcare providers must assess baseline cardiovascular risk factors and monitor blood pressure, hematocrit, and prostate parameters regularly in men receiving testosterone therapy. For an in-depth review of treatment protocols and safety parameters, see our overview of testosterone replacement therapy evidence.
A common misconception in consumer health circles is that estradiol is inherently problematic and should be driven as low as possible using over-the-counter supplements or off-label aromatase inhibitors. High-quality human trials directly contradict this idea. Indiscriminate suppression of estradiol increases cardiovascular risk markers, worsens bone mineral density, increases visceral adiposity, and causes profound sexual dysfunction.
Similarly, treating serum DHT as a universal marker of vitality or vitality loss lacks clinical support. DHT levels in blood do not provide actionable insight for most adult men experiencing generalized fatigue or low mood. Safe medical practice relies on validated diagnostic protocols rather than speculative hormone manipulation. To understand our research standards, read more about our evidence-led approach to male endocrine science.
Navigating male hormone health requires open, informed communication with a knowledgeable healthcare provider. If you are experiencing persistent symptoms or have concerns about your lab results, consider raising the following targeted questions during your appointment:
Yes. If a man has high concentrations of SHBG, his bioavailable testosterone may be reduced while his total testosterone appears completely normal. Additionally, conditions that alter peripheral aromatase expression, such as significant changes in visceral adipose tissue, can shift the ratio of circulating androgens to estrogens. Evaluating symptoms alongside free testosterone, SHBG, and sensitive estradiol testing provides a clearer physiological assessment.
Androgenetic alopecia is determined primarily by the genetic sensitivity of hair follicle androgen receptors rather than circulating DHT concentrations alone. In men with genetic susceptibility, normal tissue levels of DHT are sufficient to trigger the progressive miniaturization of hair follicles on the crown and frontal scalp. Men who lack this genetic receptor sensitivity can have identical or higher DHT levels without experiencing follicular miniaturization or hair loss.
Aromatase inhibitors block the conversion of testosterone into estradiol. Because estradiol exerts strong negative feedback on the hypothalamus and pituitary gland, lowering estradiol can trigger a compensatory increase in LH and FSH secretion. This pituitary signal prompts the testes to produce more endogenous testosterone.
However, using aromatase inhibitors to artificially raise testosterone carries major potential risks. If estradiol drops too low, men frequently experience rapid bone density loss, increased joint discomfort, lipid abnormalities, and severe erectile dysfunction.
Adipose tissue contains high levels of the aromatase enzyme, which converts circulating testosterone into estradiol. Higher amounts of body fat increase overall peripheral aromatization rates, leading to higher conversion of testosterone into estrogen.
In addition, elevated visceral fat and associated insulin resistance often lower hepatic SHBG production, altering total circulating hormone concentrations. Significant weight reduction frequently lowers excessive aromatase activity, helping restore a more balanced physiological hormone profile naturally.
Testostra explains testosterone biology, testing, symptoms, lifestyle factors and TRT with careful sourcing and clear clinical limits.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra
